| Literature DB >> 21138580 |
Richard J Leach1, Susan C Craigmile, Sara A Knott, John L Williams, Elizabeth J Glass.
Abstract
BACKGROUND: Infectious disease of livestock continues to be a cause of substantial economic loss and has adverse welfare consequences in both the developing and developed world. New solutions to control disease are needed and research focused on the genetic loci determining variation in immune-related traits has the potential to deliver solutions. However, identifying selectable markers and the causal genes involved in disease resistance and vaccine response is not straightforward. The aims of this study were to locate regions of the bovine genome that control the immune response post immunisation. 195 F2 and backcross Holstein Charolais cattle were immunised with a 40-mer peptide derived from foot-and-mouth disease virus (FMDV). T cell and antibody (IgG1 and IgG2) responses were measured at several time points post immunisation. All experimental animals (F0, F1 and F2, n = 982) were genotyped with 165 microsatellite markers for the genome scan.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21138580 PMCID: PMC3019142 DOI: 10.1186/1471-2156-11-107
Source DB: PubMed Journal: BMC Genet ISSN: 1471-2156 Impact factor: 2.797
Figure 1Variation in IgG isotype responses. FMDV15 peptide specific IgG1 (A) and IgG2 (B) levels following immunisation at weeks 0 and 6 of 195 female cattle. Median (central horizontal line), quartiles (outer horizontal lines) and range (outer vertical lines) shown. Over 90% of the animals at week 0 and week 1 showed a very low IgG2 response. Thus the median and quartiles tend to zero at these weeks. All data is log10 transformed.
Figure 2Variation in T cell proliferation. Box plots depicting T cell proliferation (stimulation index) across time following immunisation with FMDV peptide. 2 ug/ml FMDV15 peptide (A), and 10 ug/ml Con A (B). Median (central horizontal line), quartiles (outer horizontal lines) and range (outer vertical lines) shown. FMDV peptide administered at week 0 and 6. All data has been log10 transformed.
All QTL located in this study
| Chr1 | Trait2 | cM3 | F4 | a5 | d5 | Var%6 |
|---|---|---|---|---|---|---|
| 2 | IgG1_week_10 | 38 | 5.60 | -0.21** | 0.26** | 5.71 |
| 3 | IgG2_week_2 | 58 | 5.93 | 0.66** | 0.40 | 6.03 |
| 4 | IgG1_week_1 | 31 | 5.35 | -0.63** | 0.34 | 5.46 |
| 4 | IgG1_week_8 | 20 | 5.17 | 0.12 | 0.17** | 1.18 |
| 4 | IgG1_week_10 | 27 | 4.92 | 0.23 | -0.47* | 5.05 |
| 4 | IgG1_AUC | 28 | 6.37* | 0.11 | -0.43* | 6.64 |
| 4 | SI_FMDV_Week_0 | 67 | 4.79 | 0.00 | -0.14** | 4.92 |
| 5 | SI_CA_Week_0 | 68 | 8.10* | -0.13* | 0.24** | 8.05 |
| 5 | SI_CA_Week_0 | 100 | 5.76 | 0.22** | -0.14 | 6.11 |
| 5 | SI_CA_Week_10 | 76 | 5.26 | -0.05 | 0.23** | 5.38 |
| 5 | SI_CA_10 ug_AUC | 69 | 5.89 | -0.06 | 0.17** | 6.04 |
| 6 | SI_CA_Week_0 | 30 | 8.69** | 0.26*** | 0.08 | 8.59 |
| 6 | SI_FMDV_Week_8 | 59 | 6.49 | 0.14** | -0.08 | 6.56 |
| 6 | SI_FMDV_Week_8 | 133 | 7.35* | 0.04 | -0.20*** | 7.51 |
| 6 | SI_FMDV_Week_10 | 3 | 6.61 | 0.12** | -0.15* | 6.67 |
| 6 | SI_FMDV_AUC | 2 | 7.91* | 0.10*** | -0.07 | 7.96 |
| 6 | SI_FMDV_AUC | 133 | 6.21 | 0.03 | -0.13** | 6.56 |
| 7 | IgG2_week_8 | 0 | 6.24 | -0.85*** | 0.13 | 6.58 |
| 7 | SI_CA_Week_10 | 0 | 4.89 | 0.05 | 0.28** | 5.02 |
| 7 | SI_FMDV_Week_4 | 54 | 5.45 | -0.11** | -0.09 | 5.62 |
| 9 | IgG1_week_0 | 40 | 5.29 | -0.2948* | 0.35 | 5.41 |
| 9 | SI_FMDV_Week_10 | 63 | 4.92 | 0.05 | -0.23** | 5.05 |
| 11 | IgG1_week_0 | 0 | 5.26 | 0.25 | -0.61* | 5.38 |
| 12 | IgG2_week_8 | 17 | 5.44 | -0.03 | 1.24*** | 5.56 |
| 13 | IgG1_week_1 | 0 | 5.08 | 0.04 | -0.54** | 5.20 |
| 14 | IgG2_week_0 | 2 | 4.85 | 0.12 | -0.28** | 4.98 |
| 15 | IgG2_week_8 | 13 | 5.16 | -0.08 | 1.03** | 5.28 |
| 15 | IgG2_AUC | 27 | 5.39 | -0.08 | 0.67** | 5.51 |
| 16 | IgG2_week_2 | 76 | 6.51 | -0.71*** | -0.16 | 6.58 |
| 16 | SI_FMDV_AUC | 64 | 4.42 | -0.06* | -0.07* | 4.61 |
| 18 | SI_CA_Week_10 | 22 | 7.02* | -0.20*** | 0.10 | 7.06 |
| 18 | IgG2_week_1 | 57 | 5.23 | -0.10 | 0.34** | 5.40 |
| 19 | IgG2_week_2 | 28 | 4.93 | -0.50* | -0.62* | 5.06 |
| 19 | IgG2_week_4 | 34 | 5.64 | -0.73*** | -0.32 | 5.75 |
| 19 | IgG2_week_8 | 50 | 5.28 | -0.81** | -0.25 | 5.63 |
| 19 | SI_CA_Week_8 | 32 | 8.57* | 0.25*** | -0.07 | 8.48 |
| 19 | SI_CA_Week_10 | 32 | 4.54 | 0.15* | -0.13 | 4.67 |
| 19 | SI_CA_10 ug_AUC | 28 | 4.42 | 0.13** | -0.01 | 4.61 |
| 20 | IgG1_week_2 | 28 | 4.74 | -0.03 | 0.48** | 4.87 |
| 20 | IgG1_week_4 | 36 | 7.86* | 0.20** | 0.35** | 7.83 |
| 20 | IgG1_week_8 | 9 | 6.49* | 0.19 | 0.64** | 6.56 |
| 20 | IgG1_week_10 | 23 | 5.37 | 0.09 | 0.38** | 5.48 |
| 20 | IgG1_AUC | 20 | 10.07*** | 0.12 | 0.39*** | 9.82 |
| 20 | IgG2_week_4 | 32 | 7.48 | 0.52** | 0.65* | 7.48 |
| 20 | IgG2_week_8 | 25 | 8.46 | 0.76** | 0.87* | 8.38 |
| 20 | IgG2_week_10 | 31 | 6.23 | 0.33 | 0.82** | 6.31 |
| 20 | IgG2_AUC | 31 | 8.5* | 0.40** | 0.67** | 8.41 |
| 20 | SI_FMDV_Week_0 | 61 | 7.95* | 0.05 | -0.18*** | 7.92 |
| 21 | IgG1_week_2 | 69 | 4.96 | -0.22* | 0.38* | 5.09 |
| 21 | SI_CA_10 ug_AUC | 84 | 4.10 | -0.14** | -0.01 | 4.28 |
| 23 | IgG1_week_0 | 78 | 5.11 | -0.19 | -0.54** | 5.24 |
| 23 | IgG1_week_1 | 65 | 5.83 | -0.13 | -0.87*** | 5.92 |
| 23 | IgG1_week_2 | 39 | 4.16 | 0.37 | -0.53 | 4.31 |
| 23 | IgG1_week_10 | 18 | 5.25 | 0.37** | 0.03 | 5.37 |
| 23 | IgG1_AUC | 18 | 5.34 | 0.29** | 0.06 | 5.46 |
| 23 | IgG2_week_4 | 0 | 5.45 | 0.63** | -0.18 | 5.57 |
| 23 | IgG2_week_8 | 5 | 5.85 | 0.88*** | -0.18 | 5.94 |
| 23 | IgG2_week_10 | 33 | 4.08 | 1.02** | 0.77 | 4.23 |
| 23 | IgG2_AUC | 6 | 6.61* | 0.66*** | -0.18 | 6.67 |
| 24 | IgG1_week_8 | 35 | 7.83** | 0.58*** | 0.32 | 7.80 |
| 24 | IgG1_week_10 | 33 | 4.18 | 0.27** | 0.06 | 4.32 |
| 24 | IgG1_AUC | 33 | 6.23 | 0.25*** | 0.12 | 6.31 |
| 24 | IgG2_week_10 | 21 | 5.09 | 0.69** | 0.61 | 5.32 |
| 24 | SI_CA_Week_4 | 34 | 5.46 | -0.05 | 0.28** | 5.63 |
| 25 | IgG1_week_0 | 0 | 4.48 | 0.34* | 0.28 | 4.62 |
| 25 | IgG1_week_1 | 0 | 4.88 | 0.29* | 0.35* | 5.01 |
| 25 | IgG1_week_2 | 33 | 4.42 | 0.05 | -0.35** | 4.66 |
| 25 | IgG2_week_1 | 15 | 4.48 | 0.18** | -0.11 | 4.62 |
| 25 | IgG2_week_2 | 34 | 4.65 | -0.14 | -0.73** | 4.78 |
| 25 | IgG2_week_4 | 34 | 4.85 | -0.14 | -0.70** | 4.98 |
| 25 | IgG2_AUC | 34 | 5.28 | -0.04 | -0.62** | 5.40 |
| 25 | SI_CA_Week_10 | 17 | 5.79 | -0.11* | 0.19** | 5.89 |
| 26 | IgG1_week_1 | 21 | 4.90 | -0.30* | 0.35 | 5.25 |
| 27 | IgG2_week_4 | 7 | 4.61 | -0.57** | -0.33 | 4.75 |
| 29 | SI_CA_Week_0 | 0 | 5.34 | 0.15** | -0.11 | 5.69 |
| 29 | SI_FMDV_Week_8 | 7 | 4.90 | -0.10* | 0.12 | 5.03 |
| 29 | SI_FMDV_Week_10 | 0 | 4.38 | -0.11** | 0.08 | 4.61 |
1. Chr: the chromosome number of the QTL. Underlined if 2 QTL model.
2. Trait: each trait is shown as follows: trait type (IgG1; IgG2; SI_FMDV = T cell proliferation to the FMDV peptide; SI_CA = T cell proliferation to Concanavalin A), followed by week post immunisation.
3. cM: the position the QTL is on the chromosome, in centiMorgans.
4. F: the F-statistic for each QTL. Significance level: all are at least 5% chromosome wide, * = p < 1% chromosome wide, **= p < 5% genome wide and ***= p < 1% genome wide.
5. "a" and "d" are the additive and dominance effect, respectively, of each QTL, * = p < 5%, **= p < 1% and ***= p < 0.01%.
6. Var%: the phenotypic variance explained by the QTL.
Clusters of related traits have been boxed, 6 in total
Chromosomal positions of all QTL
| BTA number3 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IgG1 | 0 | x4 | x | x | x | |||||||||
| 1 | x | x | x | x | x | |||||||||
| 2 | x | x | x | x | ||||||||||
| 4 | x | |||||||||||||
| 8 | x | x | x | |||||||||||
| 10 | x | x | x | x | x | |||||||||
| 14 | 18 | 25 | 3 | 16 | 19 | 27 | 20 | 23 | 7 | 12 | 15 | 24 | ||
| IgG2 | 0 | x | ||||||||||||
| 1 | x | x | ||||||||||||
| 2 | x | x | x | x | ||||||||||
| 4 | x | x | x | x | x | |||||||||
| 8 | x | x | x | x | x | x | ||||||||
| 10 | x | x | x | |||||||||||
| 4 | 20 | 6 | 7 | 29 | 9 | |||||||||
| T-cell FMDV | 0 | x | x | x | ||||||||||
| 4 | x | |||||||||||||
| 8 | xx | x | ||||||||||||
| 10 | x | x | x | |||||||||||
| 29 | 6 | 5 | 24 | 19 | 25 | 7 | 18 | |||||||
| T-cell ConA | 0 | x | x | xx | ||||||||||
| 4 | x | |||||||||||||
| 8 | x | |||||||||||||
| 10 | x | x | x | x | x | |||||||||
1. Trait = immune response type to the FMDV15 peptide
2. Week post immunisation
3. Bos Taurus Autosome (BTA) number
4. Each 'X' represents the presence of a QTL, 'XX' represents 2 QTL. All are at least 5% chromosome wide significant
(AUC results are omitted as they are representative of the overall response across time.)
Figure 3BTA23: Significant QTL. F-statistic profile and support intervals for IgG1 and IgG2 responses (AUC = area under curve) elicited by FMDV15 peptide, located on chromosome 23. The constant horizontal line represents the threshold of the 1% chromosome wide significance (F = 5.90). Traits are described as Table 1.
Figure 4BTA20: Significant QTL. F-statistic profile for IgG1 and IgG2 responses (AUC = area under curve) elicited by FMDV15 peptide, located on chromosome 20. The dashed horizontal line represents the threshold of the 1% genome wide significance (F = 9.94). The dot-dashed line represents the threshold of the 5% genome wide significance (F = 8.10). Traits are described as Table 1.
Figure 5BTA6: 2 Significant QTL. F-statistic profiles for two QTL on BTA6 for the T cell proliferation to FMDV15 peptide at week 8. The peak of QTL A occurs at 59 cM. Following the addition of QTL A as a background effect, QTL B was revealed. The peak of QTL B is at 133 cM. The horizontal line is the 1% chromosome wide significance level (F = 6.85). Traits are described as Table 1.